Skip to main content

Atugen Reaches Nine Milestones in Schering Target Validation Deal

NEW YORK, May 9 (GenomeWeb News) - Atugen said today that it reached nine milestones under its target validation research deal with German drug maker Schering and its US subsidiary, Berlex Biosciences.

 

According to Atugen, it received milestone payments on nine of Scheing's cancer drug targets that were validated by Atugen using its proprietary gene-silencing technologies since the companies began working together in 2002.

 

Financial terms of the arrangement, which an Atugen spokeswoman said has now been completed, are undisclosed.

 

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.